|
|
免疫检查点在胃癌中的研究进展
|
Abstract:
胃癌是全球最常见的消化道肿瘤之一。由于其晚期的患者预后较差，单纯传统的化疗效果并不能满足患者治疗需求，因此挖掘新的治疗策略来改善该疾病的生存率势在必行。目前程序性死亡受体1 (programmed cell death 1, PD-1)抑制剂联合化疗已用于晚期胃癌一线治疗。随着对胃癌免疫基因组学的进一步了解，新的免疫检查点调节剂可能变得更加重要，人们越来越关注在先进的姑息治疗环境中寻找可成药的靶点，发现新的预测生物标志物和实现个性化治疗势在必行。对免疫系统功能的进一步研究和认识将有助于未来免疫治疗的发展。
Gastric cancer is one of the most frequent tumors in the digestive tract. Due to the poor prognosis of patients with its advanced stage, the effect of traditional chemotherapy alone cannot meet the patients’ therapeutic needs, so it is imperative to explore new therapeutic strategies to improve the survival rate of this disease. Currently, programmed cell death 1 (PD-1) inhibitors combined with chemotherapy have been used as the first-line treatment for advanced gastric cancer. With further understanding of the immunogenomics of gastric cancer, new immune checkpoint modulators are likely to become more important, and there is a growing interest in finding druggable targets in the advanced palliative care setting, where the discovery of new predictive biomarkers and the realization of personalized therapy are imperative. Further research and understanding of immune system function will contribute to the future development of immunotherapy.
| [1] | Smyth, E.C., Nilsson, M., Grabsch, H.I., Van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. The Lancet, 396, 635-648. https://doi.org/10.1016/S0140-6736(20)31288-5 |
| [2] | Ajani, J.A., D’Amico, T.A., Bentrem, D.J., et al. (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, 20, 167-192. https://doi.org/10.6004/jnccn.2022.0008 |
| [3] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [4] | Chandra, R., Balachandar, N., Wang, S., et al. (2021) The Changing Face of Gastric Cancer: Epidemiologic Trends and Advances in Novel Therapies. Cancer Gene Therapy, 28, 390-399. https://doi.org/10.1038/s41417-020-00234-z |
| [5] | Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108 |
| [6] | Sexton, R.E., Al Hallak, M.N., Diab, M., et al. (2020) Gastric Cancer: A Comprehensive Review of Current and Future Treatment Strategies. Cancer and Metastasis Reviews, 39, 1179-1203. https://doi.org/10.1007/s10555-020-09925-3 |
| [7] | Ono, H., Yao, K., Fujishiro, M., et al. (2021) Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer (Second Edition). Digestive Endoscopy, 33, 4-20. https://doi.org/10.1111/den.13883 |
| [8] | Song, Z., Wu, Y., Yang, J., et al. (2017) Progress in the Treatment of Advanced Gastric Cancer. Tumor Biology, 39. https://doi.org/10.1177/1010428317714626 |
| [9] | Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2 |
| [10] | Liu, J., Chen, Z., Li, Y., et al. (2021) PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in Pharmacology, 12, Article ID: 731798. https://doi.org/10.3389/fphar.2021.731798 |
| [11] | Gordon, S.R., Maute, R.L., Dulken, B.W., et al. (2017) PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature, 545, 495-499. https://doi.org/10.1038/nature22396 |
| [12] | Shitara, K., Van Cutsem, E., Bang, Y.J., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370 |
| [13] | Rowshanravan, B., Halliday, N. and Sansom, D.M. (2018) CTLA-4: A Moving Target in Immunotherapy. Blood, 131, 58-67. https://doi.org/10.1182/blood-2017-06-741033 |
| [14] | Xu, X., Dennett, P., Zhang, J., et al. (2023) CTLA4 Depletes T Cell Endogenous and Trogocytosed B7 Ligands via Cis-Endocytosis. Journal of Experimental Medicine, 220, e20221391. https://doi.org/10.1084/jem.20221391 |
| [15] | Pereira, M.A., Castria, T.B., Ramos, M., et al. (2021) Cytotoxic T‐Lymphocyte‐Associated Protein 4 in Gastric Cancer: Prognosis and Association with PD‐L1 Expression. Journal of Surgical Oncology, 124, 1040-1050. https://doi.org/10.1002/jso.26604 |
| [16] | Westermann-Clark, E., Ballow, M. and Walter, J.E. (2022) The New Quest in CTLA-4 Insufficiency: How to Immune Modulate Effectively? Journal of Allergy and Clinical Immunology, 149, 543-546. https://doi.org/10.1016/j.jaci.2021.11.020 |
| [17] | Ralph, C., Elkord, E., Burt, D.J., et al. (2010) Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16, 1662-1672. https://doi.org/10.1158/1078-0432.CCR-09-2870 |
| [18] | Evrard, C., Louvet, C., Hajbi, F.E., et al. (2021) PRODIGE 59-DURIGAST Trial: A Randomised Phase II Study Evaluating FOLFIRI？ ？Durvalumab ± Tremelimumab in Second-Line of Patients with Advanced Gastric Cancer. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53, 420-426. https://doi.org/10.1016/j.dld.2020.11.036 |
| [19] | Guo, Y., Feng, Y., Fan, P., et al. (2022) Expression and Clinical Significance of KLRG1 and 2B4 on T Cells in the Peripheral Blood and Tumour of Patients with Cervical Cancer. Immunological Investigations, 51, 670-687. https://doi.org/10.1080/08820139.2020.1867567 |
| [20] | Tessmer, M.S., Fugere, C., Stevenaert, F., et al. (2007) KLRG1 Binds Cadherins and Preferentially Associates with SHIP-1. International Immunology, 19, 391-400. https://doi.org/10.1093/intimm/dxm004 |
| [21] | Herndler-Brandstetter, D., Ishigame, H., Shinnakasu, R., et al. (2018) KLRG1 Effector CD8 T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity, 48, 716-729.E8. https://doi.org/10.1016/j.immuni.2018.03.015 |
| [22] | 钱恒君. 局部晚期鼻咽癌患者外周血中淋巴细胞亚群KLRG1表达及预后分析[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2022. |
| [23] | Li, L., Wan, S., Tao, K., et al. (2016) KLRG1 Restricts Memory T Cell Antitumor Immunity. Oncotarget, 7, 61670-61678. https://doi.org/10.18632/oncotarget.11430 |
| [24] | Liu, L., You, X., Han, S., et al. (2021) CD155/TIGIT, a Novel Immune Checkpoint in Human Cancers (Review). Oncology Reports, 45, 835-845. https://doi.org/10.3892/or.2021.7943 |
| [25] | Yu, X., Harden, K., Gonzalez, L.C., et al. (2009) The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells. Nature Immunology, 10, 48-57. https://doi.org/10.1038/ni.1674 |
| [26] | Chauvin, J.M., Pagliano, O., Fourcade, J., et al. (2015) TIGIT and PD-1 Impair Tumor Antigen-Specific CD8 T Cells in Melanoma Patients. Journal of Clinical Investigation, 125, 2046-2058. https://doi.org/10.1172/JCI80445 |
| [27] | Wolf, Y., Anderson, A.C. and Kuchroo, V.K. (2020) TIM3 Comes of Age as an Inhibitory Receptor. Nature Reviews Immunology, 20, 173-185. https://doi.org/10.1038/s41577-019-0224-6 |
| [28] | Koyama, S., Akbay, E.A., Li, Y.Y., et al. (2016) Adaptive Resistance to Therapeutic PD-1 Blockade Is Associated with Upregulation of Alternative Immune Checkpoints. Nature Communications, 7, Article No. 10501. |
| [29] | Ngiow, S.F., Von Scheidt, B., Akiba, H., et al. (2011) Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer Research, 71, 3540-3551. https://doi.org/10.1158/0008-5472.CAN-11-0096 |
| [30] | Cheng, G., Li, M., Wu, J., et al. (2015) Expression of Tim-3 in Gastric Cancer Tissue and Its Relationship with Prognosis. International Journal of Clinical and Experimental Pathology, 8, 9452-9457. |
| [31] | Park, Y., Seo, A.N., Koh, J., et al. (2021) Expression of the Immune Checkpoint Receptors PD-1, LAG3, and TIM3 in the Immune Context of Stage II and III Gastric Cancer by Using Single and Chromogenic Multiplex Immunohistochemistry. Oncoimmunology, 10, Article ID: 1954761. https://doi.org/10.1080/2162402X.2021.1954761 |
| [32] | Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews. Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239 |
| [33] | Andrews, L.P., Marciscano, A.E., Drake, C.G., et al. (2017) LAG3 (CD223) as a Cancer Immunotherapy Target. Immunological Reviews, 276, 80-96. https://doi.org/10.1111/imr.12519 |
| [34] | Li, N., Jilisihan, B., Wang, W., et al. (2018) Soluble LAG3 Acts as a Potential Prognostic Marker of Gastric Cancer and Its Positive Correlation with CD8 T Cell Frequency and Secretion of IL-12 and INF-γ in Peripheral Blood. Cancer Biomarkers: Section A of Disease Markers, 23, 341-351. https://doi.org/10.3233/CBM-181278 |
| [35] | Lv, K., Li, R., Cao, Y., et al. (2021) Lymphocyte-Activation Gene 3 Expression Associates with Poor Prognosis and Immunoevasive Contexture in Epstein-Barr Virus-Positive and MLH1-Defective Gastric Cancer Patients. International Journal of Cancer, 148, 759-768. https://doi.org/10.1002/ijc.33358 |
| [36] | Raufi, A.G. and Klempner, S.J. (2015) Immunotherapy for Advanced Gastric and Esophageal Cancer: Preclinical Rationale and Ongoing Clinical Investigations. Journal of Gastrointestinal Oncology, 6, 561-569. |
| [37] | Webb, G.J., Hirschfield, G.M. and Lane, P.J.L. (2016) OX40, OX40L and Autoimmunity: A Comprehensive Review. Clinical Reviews in Allergy & Immunology, 50, 312-332. https://doi.org/10.1007/s12016-015-8498-3 |
| [38] | Cebada, J., Perez-Santos, M., Bandala, C., et al. (2021) OX40 Agonists for Cancer Treatment: A Patent Review. Expert Opinion on Therapeutic Patents, 31, 81-90. https://doi.org/10.1080/13543776.2021.1825688 |
| [39] | Redmond, W.L., Ruby, C.E. and Weinberg, A.D. (2009) The Role of OX40-Mediated Co-Stimulation in T-Cell Activation and Survival. Critical Reviews in Immunology, 29, 187-201. https://doi.org/10.1615/CritRevImmunol.v29.i3.10 |
| [40] | Dong, C., Juedes, A.E., Temann, U.A., et al. (2001) ICOS Co-Stimulatory Receptor Is Essential for T-Cell Activation and Function. Nature, 409, 97-101. https://doi.org/10.1038/35051100 |
| [41] | Amatore, F., Gorvel, L. and Olive, D. (2020) Role of Inducible Co-Stimulator (ICOS) in Cancer Immunotherapy. Expert Opinion on Biological Therapy, 20, 141-150. https://doi.org/10.1080/14712598.2020.1693540 |
| [42] | Collin, M. (2016) Immune Checkpoint Inhibitors: A Patent Review (2010-2015). Expert Opinion on Therapeutic Patents, 26, 555-564. https://doi.org/10.1080/13543776.2016.1176150 |
| [43] | Oda, S.K., Anderson, K.G., Ravikumar, P., et al. (2020) A Fas-4-1BB Fusion Protein Converts a Death to a Pro-Survival Signal and Enhances T Cell Therapy. The Journal of Experimental Medicine, 217, e20191166. https://doi.org/10.1084/jem.20191166 |
| [44] | Segal, N.H., Logan, T.F., Hodi, F.S., et al. (2017) Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23, 1929-1936. https://doi.org/10.1158/1078-0432.CCR-16-1272 |
